| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
68,370,000 |
| Market
Cap: |
51.11(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.7173 - $3.06 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Kezar Life Sciences is a clinical-stage biotechnology company, discovering and developing small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer. Co.'s primary product candidate, KZR-616, is a selective immunoproteasome inhibitor. KZR-261 is the main clinical candidate from Co.'s research platform targeting the Sec61 translocon and the protein secretion pathway for the discovery and development of small molecule therapeutics for oncology and autoimmune indications. KZR-261 has demonstrated anti-tumor activity in preclinical models of both solid and hematologic malignancies by targeting multiple pathways driving tumor growth and survival.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
541,059 |
| Total Sell Value |
$0 |
$0 |
$0 |
$3,831,730 |
| Total People Sold |
0 |
0 |
0 |
1 |
| Total Sell Transactions |
0 |
0 |
0 |
19 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Kirk Christopher J. |
President and CSO |
• • – |
2019-08-09 |
4 |
B |
$4.97 |
$24,830 |
D/D |
5,000 |
297,934 |
2.81 |
- |
|
| Fowler John Franklin |
CEO |
• • – |
2019-08-09 |
4 |
B |
$5.01 |
$3,761 |
I/I |
750 |
293,954 |
2.58 |
- |
|
| Fowler John Franklin |
CEO |
• • – |
2019-08-09 |
4 |
B |
$5.26 |
$2,628 |
D/D |
500 |
293,204 |
2.73 |
- |
|
| Belsky Marc |
CFO |
• – – |
2019-07-26 |
4 |
B |
$5.80 |
$325 |
I/I |
56 |
500 |
1.91 |
- |
|
| Belsky Marc |
CFO |
• – – |
2019-07-25 |
4 |
B |
$5.65 |
$2,510 |
I/I |
444 |
444 |
1.91 |
- |
|
| Economides Vassiliki |
SVP, Strategy & External Aff. |
• – – |
2019-07-22 |
4 |
B |
$5.82 |
$2,509 |
D/D |
431 |
431 |
2.66 |
- |
|
| Economides Vassiliki |
SVP, Strategy & External Aff. |
• – – |
2019-05-30 |
4 |
B |
$10.19 |
$7,643 |
D/D |
750 |
11,320 |
2.74 |
- |
|
| Steyer Thomas F |
Former 10% owner |
– – – |
2018-06-25 |
4 |
A |
$0.00 |
$0 |
I/I |
336,253 |
125,927 |
|
- |
|
| Bay City Capital Fund Llc |
10% Owner |
– – • |
2018-06-25 |
4 |
B |
$15.00 |
$2,250,000 |
I/I |
150,000 |
622,229 |
1.5 |
- |
|
| Bay City Capital Fund Llc |
10% Owner |
– – • |
2018-06-25 |
4 |
A |
$0.00 |
$0 |
I/I |
472,229 |
472,229 |
|
- |
|
| Berger Franklin M |
Director |
– • – |
2018-06-25 |
4 |
B |
$15.00 |
$750,000 |
D/D |
50,000 |
563,157 |
2.39 |
- |
|
| Berger Franklin M |
Director |
– • – |
2018-06-25 |
4 |
A |
$0.00 |
$0 |
D/D |
459,983 |
513,157 |
|
- |
|
| Morningside Venture Investments Ltd |
10% Owner |
– – • |
2018-06-25 |
4 |
B |
$15.00 |
$3,750,000 |
D/D |
250,000 |
2,309,052 |
2.45 |
- |
|
| Morningside Venture Investments Ltd |
10% Owner |
– – • |
2018-06-25 |
4 |
A |
$0.00 |
$0 |
D/D |
2,059,052 |
2,059,052 |
|
- |
|
| Kauffman Michael |
Director |
– • – |
2018-06-25 |
4 |
A |
$0.00 |
$0 |
D/D |
10,516 |
63,690 |
|
- |
|
| Aberdare Management Company, Llc |
10% Owner |
– – • |
2018-06-25 |
4 |
A |
$0.00 |
$0 |
D/D |
136,643 |
136,643 |
|
- |
|
| Sommadossi Jean-Pierre |
Director |
– • – |
2018-06-25 |
4 |
A |
$0.00 |
$0 |
I/I |
87,839 |
178,440 |
|
- |
|
| Cormorant Global Healthcare Master Fund, Lp |
10% Owner |
– – • |
2018-06-25 |
4 |
B |
$15.00 |
$3,750,000 |
I/I |
250,000 |
1,572,909 |
1.5 |
- |
|
| Cormorant Global Healthcare Master Fund, Lp |
10% Owner |
– – • |
2018-06-25 |
4 |
A |
$0.00 |
$0 |
I/I |
1,322,909 |
1,322,909 |
|
- |
|
| A.m. Pappas & Associates, Llc |
10% Owner |
– – • |
2018-06-25 |
4 |
A |
$0.00 |
$0 |
I/I |
314,818 |
23,894 |
|
- |
|
| Chiesi Giacomo |
10% Owner |
– – • |
2018-06-25 |
4 |
A |
$0.00 |
$0 |
I/I |
314,819 |
314,819 |
|
- |
|
| Amgen Inc |
10% Owner |
– – • |
2018-06-25 |
4 |
A |
$0.00 |
$0 |
D/D |
1,121,384 |
1,121,384 |
|
- |
|
| Paster Anne-Mari |
Former 10% Owner |
– – – |
2018-06-25 |
4 |
A |
$0.00 |
$0 |
I/I |
693,272 |
693,272 |
|
- |
|
| Paster Anne-Mari |
Former 10% Owner |
– – – |
2018-06-25 |
4 |
A |
$0.00 |
$0 |
D/D |
693,272 |
693,272 |
|
- |
|
74 Records found
|
|
Page 3 of 3 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.03 (3.26%) 
